ArticleACS chemical neuroscience2011
Tuning photochromic ion channel blockers.
Article in ACS chemical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Toward Chromoselective Transformations in Biological Systems: Perspectives and Challenges.Angewandte Chemie (International ed. in English) · 2026Review
- Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.Nature medicine · 2026Article
- Multimodal Photoswitchable Modulation of Insect Glutamatergic Transmission by Quaternary Ammonium Azobenzenes.ACS omega · 2026Article
- Ion Channel-Targeting Toxins: Structural Mechanisms of Activation, Inhibition, and Therapeutic Potential.Toxins · 2025Review
- Photoisomerization of Azobenzene-Extended Charybdotoxin for the Optical Control of KAngewandte Chemie (International ed. in English) · 2025Article
- Computational Study on the Photo-Induced Antibiotic Activity of an Azoquinolone with Promising Applications in Photopharmacology.ChemPhotoChem · 2025Article
- A membrane-targeted photoswitch restores physiological ON/OFF responses to light in the degenerate retina.Nature communications · 2025Article
- Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.Advanced healthcare materials · 2024Review
- Optical Control of G-Actin with a Photoswitchable Latrunculin.Journal of the American Chemical Society · 2024Article
- Article
- Investigation on NovelMolecules (Basel, Switzerland) · 2023Article
- Light-responsive biomaterials for ocular drug delivery.Drug delivery and translational research · 2023Review
- Effect of stacking interactions on charge transfer states in photoswitches interacting with ion channels.Physical chemistry chemical physics : PCCP · 2023Article
- Thermal Half-Lives of Azobenzene Derivatives: Virtual Screening Based on Intersystem Crossing Using a Machine Learning Potential.ACS central science · 2023Article
- Photochemical Restoration of Light Sensitivity in the Degenerated Canine Retina.Pharmaceutics · 2022Article
- Next Generation Opto-Jasplakinolides Enable Local Remodeling of Actin Networks.Angewandte Chemie (International ed. in English) · 2022Article
- Fast relaxing red and near-IR switchable azobenzenes with chalcogen and halogen substituents: periodic trends, tuneable thermal half-lives and chalcogen bonding.Chemical science · 2022Article
- New tricks and emerging applications from contemporary azobenzene research.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022Article
- Design, synthesis and biological evaluation of light-driven on-off multitarget AChE and MAO-B inhibitors.RSC medicinal chemistry · 2022Article
- Advances and opportunities in the exciting world of azobenzenes.Nature reviews. Chemistry · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Photochromic channel blockers provide a conceptually simple and convenient way to modulate neuronal activity with light. We have recently described a family of azobenzenes that function as tonic blockers of K(v) channels but require UV-A light to unblock and need to be actively switched by toggling between two different wavelengths. We now introduce red-shifted compounds that fully operate in the visible region of the spectrum and quickly turn themselves off in the dark. Furthermore, we have developed a version that does not block effectively in the dark-adapted state, can be switched to a blocking state with blue light, and reverts to the inactive state automatically. Photochromic blockers of this type could be useful for the photopharmacological control of neuronal activity under mild conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.